Clincosm LogoSign in Get a demo

CARBON: UAB Cardiovascular Research Biobank

Sponsor
University of Alabama at Birmingham (Other)
Overall Status
Recruiting
CT.gov ID
NCT05067231
Collaborator
(none)
500
Enrollment
1
Location
48
Anticipated Duration (Months)
10.4
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The UAB Cardiovascular Research Biobank (CARBON) will be a resource that contains biological materials, such as DNA samples, in addition to health and personal information on a large number of people over time. It will be set up so that it can be used in the future as a resource for researchers undertaking a wide range of medical research.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The UAB Cardiovascular Research Biobank (CARBON) will be a resource that contains pertinent genetic, health, and biological samples such as blood derived from a large-scale population. Researchers may use disease correlates and predictors identified from the genetic, health, and personal information contained in the Biobank as a resource to investigate cardiovascular disease, hypertension, diabetes, and a myriad of other disorders. Through these studies, researchers may identify the progression of risk factors in certain diseases and help develop novel strategies to detect, treat, or prevent such diseases. In addition, the Biobank serves as a valuable tool to assess how certain treatments may respond differently to individuals as a result of genotypic differences.

    The investigators have demonstrated that lower natriuretic peptide (NP) levels are associated with a decreased insulin sensitivity and have a causal role in the development of diabetes and have also shown that certain populations, such as African Americans, have relatively low NP levels, which may contribute to their underlying risk for insulin resistance. Since NPs play an important role in the regulation of insulin sensitivity, one can infer that relatively low NP levels are an important biological contributor to the high prevalence rates of cardiometabolic disease in African Americans. The Biobank will contain genetic information concerning the presence of gene variants that encode NPs.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    500 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    UAB Cardiovascular Research Biobank
    Actual Study Start Date :
    Jan 1, 2022
    Anticipated Primary Completion Date :
    Jan 1, 2026
    Anticipated Study Completion Date :
    Jan 1, 2026

    Outcome Measures

    Primary Outcome Measures

    1. Genetic Variants in the NPPA and NPPB gene of the Natriuretic Peptide family associated with the Cardiovascular and Metabolic Diseases [Baseline]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Age more than or equal to 18
    Exclusion Criteria:

    • Age <18, at screening

    • Employees or students associated with the Division of Cardiovascular Disease at UAB will not be recruited due to their vulnerable status and susceptibility to coercion.

    • Women who are pregnant or who can become pregnant and not practicing an acceptable method of birth control.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Alabama at Birmingham Birmingham Alabama United States 35294

    Sponsors and Collaborators

    • University of Alabama at Birmingham

    Investigators

    • Principal Investigator: Pankaj Arora, MD, FAHA, University of Alabama at Birmingham

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Pankaj Arora, MD, Assistant Professor, Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham
    ClinicalTrials.gov Identifier:
    NCT05067231
    Other Study ID Numbers:
    • IRB - 300007834
    First Posted:
    Oct 5, 2021
    Last Update Posted:
    Jun 8, 2022
    Last Verified:
    Jun 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Pankaj Arora, MD, Assistant Professor, Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham
    Natriuretic Peptides
    Cardiovascular Diseases
    Hypertension
    Diabetes
    Obesity
    Additional relevant MeSH terms:
    Hypertension
    Cardiovascular Diseases

    Study Results

    No Results Posted as of Jun 8, 2022